Pharmacokinetics of soy-derived lysophosphatidylcholine compared with that of glycerophosphocholine: a randomized controlled trial.
Biosci Biotechnol Biochem
; 88(6): 648-655, 2024 May 22.
Article
en En
| MEDLINE
| ID: mdl-38490741
ABSTRACT
Lysophosphatidylcholine (LPC) is present in various foods and contains a choline moiety such as in glycerophosphocholine (GPC). However, the potential of LPC as a choline source remains unclear. This study investigated the single-dose pharmacokinetics of 480 mg soy-derived LPC in 12 healthy men compared with that of either soy oil with the same lipid amount (placebo) or GPC with the same choline amount. Both LPC and GPC supplementation increased plasma choline, serum phospholipid, and serum triglyceride concentrations, but neither of them significantly elevated plasma trimethylamine N-oxide concentration. In addition, although the intake of LPC slightly increased plasma LPC160, LPC182, and total LPC concentrations, their concentrations remained within physiological ranges. No adverse events were attributed to the LPC supplementation. To the best of our knowledge, this study is the first to compare LPC and GPC pharmacokinetics in humans and shows that LPC can be a source of choline.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Glycine max
/
Lisofosfatidilcolinas
/
Colina
/
Glicerilfosforilcolina
Idioma:
En
Revista:
Biosci Biotechnol Biochem
/
Biosci. biotechnol. biochem
/
Bioscience, biotechnology, and biochemistry
Año:
2024
Tipo del documento:
Article
País de afiliación:
Japón